0001193125-23-296402.txt : 20240119 0001193125-23-296402.hdr.sgml : 20240119 20231215115357 ACCESSION NUMBER: 0001193125-23-296402 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20231215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NewAmsterdam Pharma Co N.V. CENTRAL INDEX KEY: 0001936258 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: GOOIMEER 2-35 CITY: NARRDEN STATE: P7 ZIP: 1411 DC BUSINESS PHONE: 35 206 2971 MAIL ADDRESS: STREET 1: GOOIMEER 2-35 CITY: NARRDEN STATE: P7 ZIP: 1411 DC FORMER COMPANY: FORMER CONFORMED NAME: NewAmsterdam Pharma Co B.V. DATE OF NAME CHANGE: 20220701 CORRESP 1 filename1.htm CORRESP

NewAmsterdam Pharma Company N.V.

Gooimeer 2-35

1411 DC Naarden

The Netherlands

December 15, 2023

Via EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3561

Attn: Jason Drory

 

Re:

NewAmsterdam Pharma Company N.V.

    

Registration Statement on Form F-3

    

Filed December 7, 2023

    

File No. 333-275932

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), NewAmsterdam Pharma Company N.V. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form F-3 (the “Registration Statement”) be accelerated by the Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 4:00 p.m. Eastern Time on December 19, 2023, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective.

We respectfully request that we be notified of such effectiveness by a telephone call to Brian K. Rosenzweig of Covington & Burling LLP at (212) 841-1108 and that such effectiveness also be confirmed in writing.

 

Respectfully,
NewAmsterdam Pharma Company N.V.
By:   /s/ Michael Davidson
Name:   Michael Davidson
Title:   Chief Executive Officer and Executive Director

cc: Brian K. Rosenzweig, Covington & Burling LLP